ESPR

ESPERION THERAPEUTICS INC

ESPR

Overview Fund Activity

Delisted

ESPR was delisted on the 10th of February, 2004.

Back to rankings

Healthcare Drug Manufacturers - General

Financial journalist opinion

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Cantor Global Healthcare Conference 2025 September 3, 2025 9:45 AM EDT Company Participants Benjamin Halladay - Chief Financial Officer Sheldon Koenig - President, CEO & Director Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Okay. Good morning, everybody.

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Top 2 Health Care Stocks That May Plunge This Month

As of Sept. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 2 Health Care Stocks That May Plunge This Month

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Zacks Investment Research

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

The Motley Fool

Esperion (ESPR) Q2 Revenue Jumps 12%

Esperion (ESPR) Q2 Revenue Jumps 12%

Esperion (ESPR) Q2 Revenue Jumps 12%

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Lisa Schafer - Corporate Participant Sheldon L. Koenig - President, CEO & Director Conference Call Participants Georgia Bank - Jefferies LLC, Research Division Jason Eron Zemansky - BofA Securities, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Joseph Pantginis - H.C.

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.05 per share a year ago.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL ® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich.

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Zacks Investment Research

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

See News Rankings

Charts implemented using Lightweight Charts™